Hematología y Hemoterapia

Resultados: 340
Tipo Título / Nombre Autor(es) Año
Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Alvarez RM..., Bermejo N, et al 2021
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group Palanques-Pastor T, Megías-Vericat JE, Martínez P, López Lorenzo JL, Cornago Navascués J..., Bergua Burgués JM, et al 2021
Frequency, clinical characteristics and outcome of adults with acutelymphoblastic leukemia and COVID 19 infection in the first vs.second pandemic wave in Spain Ribera JM, Morgades M, Coll R, Barba P, López-Lorenzo JL..., Bergua J, et al 2021
Concentración de hemoglobina reticulocitaria y ferroterapia en la ERC Deira J, García de la Vega C, Davín E, Arcos MJ 2021
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial Jiménez-Cortegana C, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Carnicero-González F, Ríos-Herranz E , et al 2021
The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the PETHEMA-FLUGAZA phase 3 clinical trial Ayala R, Rapado I, Onecha E, Martínez-Cuadrón D, Carreño-Tarragona G, Bergua JM, et al 2021
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients Martínez Sánchez MP, Megías-Vericat JE, Rodríguez-Veiga R, Vives S, Bergua JM, Torrent A, et al 2021
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study Rodríguez-Arbolí E, Martínez-Cuadrón D, Rodríguez-Veiga R, Carrillo-Cruz E, Gil-Cortés C..., Bergua JM, et al 2021
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Álvarez RM..., Bermejo N, et al 2021
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia Vives S, Martínez-Cuadrón D, Bergua Burgues J, Algarra L, Tormo M, Martínez-Sánchez MP, et al 2021